Form 4: LENZ Therapeutics: Versant Venture Capital Reports Ownership Changes Following Merger and Reverse Stock Split

Versant Venture Capital reports changes in beneficial ownership of LENZ Therapeutics stock following a merger and reverse stock split.

Summary

• Versant Venture Capital VI, L.P., along with related entities, reported changes in their beneficial ownership of LENZ Therapeutics, Inc. common stock on March 25, 2024.
• These changes are a result of the merger between LENZ Therapeutics, Inc. and Generate Merger Sub, Inc., a wholly-owned subsidiary of LENZ Therapeutics, Inc.
• Prior to the merger, LENZ Therapeutics, Inc. implemented a one-for-seven reverse stock split on March 21, 2024, which has been reflected in the reported amounts.
• Versant Venture Capital VI, L.P. acquired 598,203 shares and now beneficially owns 842,162 shares.
• Versant Venture Capital VI, L.P. also directly owns 2,101,199 shares.
• Versant Venture Capital VII, L.P. beneficially owns 1,598,789 shares.
• Several Versant entities, including Versant Ventures VI GP, L.P. and Versant Ventures VII GP, L.P., disclaim beneficial ownership of the shares held by their respective funds, except to the extent of their pecuniary interests.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing reflecting ownership changes. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are standard practice when significant changes in ownership occur, particularly after events like mergers and stock splits. This filing provides transparency to the market regarding the holdings of major shareholders.

Stakeholder Impact

• Shareholders are informed about the ownership structure of the company.
• The filing ensures transparency and compliance with SEC regulations.

Key Dates